trending Market Intelligence /marketintelligence/en/news-insights/trending/aFAft7ldSOVLSr95BwHmUg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Pfizer closes $5B debt offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Pfizer closes $5B debt offering

Pfizer Inc. completed a $5 billion debt offering, according to a March 11 filing.

The New York-based pharmaceutical giant offered $500 million of 2.80% notes due 2022, $750 million of 2.95% notes due 2024, $1.75 billion of 3.45% notes due 2029, $750 million of 3.90% notes due 2039 and $1.25 billion of 4% notes due 2049.

Pfizer intends to use the net proceeds for repaying existing debt and a portion of its outstanding commercial paper as well as for other general corporate purposes.

Barclays Capital Inc., Deutsche Bank Securities Inc., Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC served as joint book-running managers for the debt offering.